{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=81", "query": { "intervention": "Branch II", "page": 81 }, "page_size": 10 }, "pagination": { "page": 81, "page_size": 10, "total_count": 4760, "total_pages": 476, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=82&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=80&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T11:50:36.962Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01495988", "title": "Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Metastatic Melanoma" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Melanoma Research Foundation Breakthrough Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2013-08", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2017-10-24", "last_synced_at": "2026-11-02T11:50:36.962Z", "location_count": 14, "location_summary": "Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01495988" }, { "nct_id": "NCT00673569", "title": "Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "needle biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2006-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-08-09", "last_synced_at": "2026-11-02T11:50:36.962Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00673569" }, { "nct_id": "NCT02677805", "title": "Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glabellar Frown Lines" ], "interventions": [ { "name": "Botulinum Toxin A", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Botulinum Toxin A - Open Label", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Croma-Pharma GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 251, "start_date": "2016-03-30", "completion_date": "2017-11-03", "has_results": true, "last_update_posted_date": "2025-03-19", "last_synced_at": "2026-11-02T11:50:36.962Z", "location_count": 7, "location_summary": "Encinitas, California • Aventura, Florida • Sarasota, Florida + 4 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Hillsborough", "state": "New Jersey" }, { "city": "Mount Kisco", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02677805" }, { "nct_id": "NCT00033462", "title": "Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Primary Cholangiocellular Carcinoma", "Adult Primary Hepatocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Cholangiocarcinoma of the Extrahepatic Bile Duct", "Cholangiocarcinoma of the Gallbladder", "Localized Unresectable Adult Primary Liver Cancer", "Recurrent Adult Primary Liver Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2002-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-11-02T11:50:36.962Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00033462" }, { "nct_id": "NCT01628029", "title": "Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm", "Sleep Disorder" ], "interventions": [ { "name": "Counseling", "type": "OTHER" }, { "name": "Methylphenidate Hydrochloride", "type": "DRUG" }, { "name": "Phototherapy", "type": "PROCEDURE" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Sham Intervention", "type": "PROCEDURE" }, { "name": "Therapeutic Melatonin", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2014-01-15", "completion_date": "2028-12-31", "has_results": true, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-11-02T11:50:36.962Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01628029" }, { "nct_id": "NCT03742102", "title": "A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Datopotamab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "FEMALE", "summary": "18 Years to 130 Years · Female only" }, "enrollment_count": 243, "start_date": "2018-12-21", "completion_date": "2027-02-26", "has_results": true, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-11-02T11:50:36.962Z", "location_count": 8, "location_summary": "Tucson, Arizona • Columbia, Maryland • Boston, Massachusetts + 4 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Columbia", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03742102" }, { "nct_id": "NCT01006369", "title": "Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "hydroxychloroquine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 38, "start_date": "2009-05", "completion_date": "2016-04-27", "has_results": true, "last_update_posted_date": "2021-09-21", "last_synced_at": "2026-11-02T11:50:36.962Z", "location_count": 4, "location_summary": "Camden, New Jersey • Hamilton, New Jersey • New Brunswick, New Jersey + 1 more", "locations": [ { "city": "Camden", "state": "New Jersey" }, { "city": "Hamilton", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01006369" }, { "nct_id": "NCT00082641", "title": "Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "autologous dendritic cell-adenovirus p53 vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "19 Years to 120 Years · Female only" }, "enrollment_count": 24, "start_date": "2004-01-01", "completion_date": "2018-01-01", "has_results": true, "last_update_posted_date": "2023-09-22", "last_synced_at": "2026-11-02T11:50:36.962Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082641" }, { "nct_id": "NCT01000623", "title": "Venlafaxine and Hypnosis or Focused Attention in Treating Patients with Hot Flashes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hot Flashes" ], "interventions": [ { "name": "venlafaxine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "hypnotherapy", "type": "PROCEDURE" }, { "name": "mind-body intervention procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 71, "start_date": "2010-01-31", "completion_date": "2015-09-08", "has_results": false, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-11-02T11:50:36.962Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01000623" }, { "nct_id": "NCT00784303", "title": "Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Cancer" ], "interventions": [ { "name": "Lenvatinib (DTC Cohort)", "type": "DRUG" }, { "name": "Lenvatinib (MTC Cohort)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 117, "start_date": "2008-11-06", "completion_date": "2019-03-29", "has_results": true, "last_update_posted_date": "2020-04-22", "last_synced_at": "2026-11-02T11:50:36.962Z", "location_count": 23, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Los Gatos, California + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Gatos", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00784303" } ] }